EU regulators recommend PARP inhibitor Zejula
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
FDA approves Lynparza’s use in a wider group of women.
Circulating tumour cell test could help select drug therapy.
US biotech looks to bolster pipeline.
Tesara and Takeda among other companies to publish data.
Veliparib fails in two phase 3 trials.
Company nabs maintenance therapy use, but problems on breast cancer trial.
UK firm lays down the gauntlet in the PARP inhibitor battle.